Edition:
United States

Vitrolife AB (VITR.ST)

VITR.ST on Stockholm Stock Exchange

602.00SEK
16 Feb 2018
Change (% chg)

-38.50kr (-6.01%)
Prev Close
640.50kr
Open
640.50kr
Day's High
640.50kr
Day's Low
598.00kr
Volume
43,772
Avg. Vol
32,445
52-wk High
717.00kr
52-wk Low
415.50kr

Latest Key Developments (Source: Significant Developments)

Vitrolife hikes dividend, Q4 EBITDA up yr/yr
Thursday, 8 Feb 2018 02:30am EST 

Feb 8 (Reuters) - Vitrolife Ab ::Q4 ‍SALES AMOUNTED TO SEK 271 (251) MILLION, CORRESPONDING TO AN INCREASE OF 8 PERCENT IN SEK​.Q4 ‍SALES GROWTH WAS 11 PERCENT IN LOCAL CURRENCY AND CONSISTED IN ITS ENTIRETY OF ORGANIC GROWTH.​.Q4 ‍OPERATING INCOME BEFORE DEPRECIATION AND AMORTISATION (EBITDA) AMOUNTED TO SEK 103 (96) MILLION, CORRESPONDING TO A MARGIN OF 38 (38) PERCENT​.SAYS ‍BOARD PROPOSES A DIVIDEND OF SEK 3.70 (2.60) PER SHARE​.  Full Article

Vitrolife buys licensing rights for embryo transfer technology
Thursday, 11 Jan 2018 02:33am EST 

Jan 11 (Reuters) - Vitrolife AB ::VITROLIFE ACQUIRES LICENSING RIGHTS TO TECHNOLOGY FOR EMBRYO TRANSFER.SAYS ‍INTENDS TO COMMERCIALISE TECHNOLOGY BY MARKETING A UNIQUE EMBRYO TRANSFER CATHETER​.SAYS ‍INITIAL PURCHASE PRICE AMOUNTED TO USD 5 MILLION​.SAYS ‍ACQUISITION IS EXPECTED TO IMPACT EBITDA PER SHARE MARGINALLY NEGATIVELY DURING 2018-2020 AND POSITIVELY AS FROM 2021​.  Full Article

Vitrolife Q3 core profit rises, like-for-like sales grow 20 pct​
Thursday, 2 Nov 2017 03:30am EDT 

Nov 2 (Reuters) - Vitrolife AB :Q3 ‍sales amounted to SEK 246 (210) million, corresponding to an increase of 17 percent in SEK​.Q3 ‍sales growth was 20 percent in local currency and consisted in its entirety of organic growth​.Q3 ‍operating income before depreciation and amortisation (EBITDA) amounted to SEK 98 (71) million, corresponding to a margin of 40 (34) percent​.Says looking ahead, the market outlook is essentially unchanged.  Full Article

Vitrolife Q2 EBITDA rises to SEK 112 mln
Friday, 14 Jul 2017 02:30am EDT 

July 14 (Reuters) - Vitrolife AB :Q2 sales amounted to SEK 285 (208) million.Q2 operating income before depreciation and amortisation (EBITDA) amounted to SEK 112 (74) million.Says anticipates a constantly expanding market, which in monetary terms is expected to grow by 5-10 percent per year in the foreseeable future.  Full Article

Vitrolife Q1 EBITDA rises 53 pct yr/yr
Tuesday, 25 Apr 2017 02:30am EDT 

April 25 (Reuters) - Vitrolife AB :Q1 sales amounted to SEK 244 (187) million.Q1 operating income before depreciation and amortisation (EBITDA) amounted to SEK 95 (62) million.Q1 net sales growth was 27 percent in local currency.Looking ahead, the market outlook is essentially unchanged and Vitrolife therefore anticipates a constantly expanding market, which in monetary terms is expected to grow by 5-10 percent per year in the foreseeable future.  Full Article

Vitrolife Q4 core profit rose to SEK 96 mln
Thursday, 9 Feb 2017 02:30am EST 

Vitrolife Ab : Q4 sales amounted to SEK 251 (199) million, corresponding to an increase of 26 percent in SEK. Net sales growth was 21 percent in local currency. . Q4 operating income before depreciation and amortisation (ebitda) amounted to SEK 96 (81) million . Q4 board proposes a dividend of SEK 2.60 (2.40) per share. .Says looking ahead, the market outlook is essentially unchanged and Vitrolife therefore anticipates a constantly expanding market, which in monetary terms is expected to grow by 5-10 percent per year in the foreseeable future..  Full Article

Vitrolife Q3 EBITDA profit narrows to SEK 71 mln
Thursday, 3 Nov 2016 03:30am EDT 

Vitrolife AB : Q3 sales amounted to SEK 210 (177) million .Q3 operating income before depreciation and amortisation (EBITDA) amounted to SEK 71 (82) million.  Full Article

Vitrolife Q2 core profit rises, market outlook unchanged
Friday, 15 Jul 2016 02:30am EDT 

Vitrolife AB : Q2 sales amounted to sek 208 (184) million . Q2 operating income before depreciation and amortisation (ebitda) amounted to sek 74 (62) million, corresponding to a margin of 35 (34) percent. .Says market outlook is essentially unchanged and Vitrolife therefore anticipates a constantly expanding market, which in monetary terms is expected to grow by 5-10 percent per year in the foreseeable future.  Full Article

Vitrolife says buys OCTAX and MTG
Wednesday, 1 Jun 2016 02:37am EDT 

Vitrolife Ab : Vitrolife acquiring octax and mtg, jointly holding a world-leading position in laser technology for IVF . Vitrolife AB (publ) has completed the acquisition of 100% of the shares in OCTAX Microscience GmbH "OCTAX" and MTG Medical Technology Vertriebs-GmbH "MTG" . The consolidated net sales for the companies in 2015 amounted to approximately EUR 8.5 million (6.9) . The purchase sum for both companies amounted to EUR 13.7 million . The acquisitions are expected to be accretive to earnings per share from 2016 and onwards Further company coverage: [VITR.ST].  Full Article

BRIEF-Vitrolife hikes dividend, Q4 EBITDA up yr/yr

* Q4 ‍SALES AMOUNTED TO SEK 271 (251) MILLION, CORRESPONDING TO AN INCREASE OF 8 PERCENT IN SEK​